SB-485232

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

LymphomaLymphoma, Non-HodgkinMelanomaSolid Tumor Cancer

Phase 1

Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

CompletedNCT00085878

GlaxoSmithKlineSolid Tumor Cancer

Start: 2003-01-31Updated: 2008-10-16

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

CompletedNCT00085904

GlaxoSmithKlineLymphoma, Solid Tumor Cancer

Start: 2004-04-30Updated: 2008-10-13

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

CompletedNCT00500058

GlaxoSmithKlineLymphoma, Non-Hodgkin

Start: 2007-07-31End: 2010-03-04Updated: 2017-07-26

Phase 2

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

CompletedNCT00107718

GlaxoSmithKlineMelanoma

Start: 2004-11-15End: 2006-05-19Updated: 2017-07-27